



Worldwide contacts for additional information

World Headquarters

Ajay Rastogi
Vice President
Technology Catalysts International
605 Park Avenue
Falls Church, VA 22046, USA
Telephone: (703) 531-0257
Facsimile: (703) 237-0042
E-mail: arastogi@technology-catalysts.com

Jared Hahn
Technical Operations Manager
Technology Catalysts International Corporation
605 Park Avenue
Falls Church, VA 22046, U.S.A.
Telephone: (703) 531-0254
Facsimile: (703) 237-0042
E-mail: jhahn@technology-catalysts.com
Internet: www.technology-catalysts.com

Europe

Graham L. Crawford, MSc
Managing Director
Technology Catalysts International UK
Blacksmiths
Clifton Road
Newton Blossomville
Bedford MK43 8AS, UK
Telephone: +44 1234 881583
Facsimile: +44 1234 881027
E-mail: gcrawford@technology-catalysts.com

Gerhard Wallenwein, Ph.D.
Managing Director
Laves Chemie Consulting
Koenigsteiner Strasse 80
D-65812 Bad Soden, Germany
Telephone: +49 6196 62057
Facsimile: +49 6196 27837
E-mail: laveschemie@t-online.de
Internet: www.laveschemie.de

Jana Kuhnlova
Executive Managing Director
Inventia s.r.o.
Na Bělidle 3
150 00 Praha 5 - Smíchov, Czech Republic
Telephone: +420 2 2224 7484
Facsimile: +420 2 2421 8645
E-mail: kuhnlova@inventia.cz
Internet: www.inventia.cz

Jiri Krepelka, Ph.D.
General Manager
TCI Generics Europe
Na Bělidle 3
150 00 Praha 5 - Smíchov, Czech Republic
Telephone: +420 2 2224 7484
Facsimile: +420 2 2421 8645
E-mail: jkrepelka@technology-catalysts.com

Asia

Sansei Oka
Japanese Business Representative
Technology Catalysts International
4-18-11-101, Takada-Higashi
Kohoku-Ku, Yokohama 223-0065, Japan
Telephone: +81 45 543 5578
E-mail: soka@technology-catalysts.com

Mitsuhisa Tamura
Senior Research Associate
Sumika Technical Information Service Inc.
15 Fl., Tokyo Sumitomo Twin Bldg. (East)
27-1, Shinkawa 2-chome
Chuo-ku, Tokyo 104-0033, Japan
Telephone: +81 3 5543 5875
Facsimile: +81 3 5543 5945
E-mail: tamuram2@sc.sumitomo-chem.co.jp
Internet: www.stis.co.jp


Jaison Abraham
General Manager
TCI India
Level 4, Dynasty, 'A' Wing
Andheri-Kurla Road
Andheri East
Mumbai 400 069
India
Telephone: +91-22-4030 9499
Facsimile: +91-22-4030 9199
Mobile: +91-981932 8598
E-mail: jaison@zenara.com

R.K. Gupta
Managing Director
Industrial Development Services Limited
M-1 Kanchenjunga
18 Barakhamba Road
New Delhi 110 001, India
Telephone: +91 11 2 331 2287, 2 331 4714
Facsimile: +91 11 2 373 8227
E-mail: ids@del2.vsnl.net.in
Internet: www.ids-india.org

South America

Carlos A. Massone, M.D.
President
Qualia S.A.
Jeronimo Salguero 2533, Piso 12 "A"
1425, Buenos Aires, Argentina
Telephone: +54 11 4807 3433
Facsimile: +54 11 4807 2933
E-mail: carlos.massone@qualia.com.ar
Internet: www.qualia.com.ar

RNAi and Antisense Therapeutics



TECHNOLOGY & BUSINESS REVIEW

About Technology Catalysts International

Technology Catalysts International (TCI) was founded in 1979 to provide consulting services that satisfy the technology transfer and business research needs of industry. We specialize in technology transfer, technology assessment, and technology portfolio management. The firm is headquartered in Falls Church, Virginia; a suburb of Washington, D.C. Our global network includes offices in Japan, India, China, Argentina, the United Kingdom, Germany and the Czech Republic.

Our research staff is comprised of professionals with backgrounds in a variety of technical disciplines, with additional expertise in international marketing, licensing, finance and business development. They are skilled in providing clients with strategically important competitive information worldwide. The breadth of our experience assures clients of high quality, actionable information, and complete coverage on topics of interest.

TCI's core consulting services are based on continuous monitoring of technological product development activities on a global basis. The company provides consulting and technology transfer services to leading product developers and manufacturers in North and South America, Europe, and Asia. Our client base consists of small, medium, and large corporations.

For more information on our services and capabilities, please visit our website at:

www.technology-catalysts.com

Visit TCI's website at:
www.technology-catalysts.com

Report Summary

In the last few years, several companies have made significant progress in developing RNAi and second generation antisense technology platforms. After establishing the validity of their technologies, the companies have successfully established therapeutic programs and strong pipelines. Many companies are using proprietary technologies to identify siRNA, antisense, or other gene silencing molecules for specific targets and are developing these molecules as drugs. Some are also developing specific delivery systems for these drugs while others are collaborating with other companies, who have established delivery technologies.

As a result, 19 companies are developing 85 siRNA products and eight companies are developing 64 antisense products. These products are focused on leading therapeutic indications including cancer, cardiovascular, ophthalmic, anti-viral, respiratory, anti-inflammatory and diabetes. These pipelines are addressing five of the top ten therapeutic classes. These are oncologics, lipid regulators, respiratory agents, antidiabetics, and autoimmune or anti-inflammatory. The five leading categories amount to \$141.1 billion in 2007 worldwide sales.

The importance of RNAi and antisense therapeutics to Big Pharma is reinforced by the acquisitions of Sirna and Mirus Bio by Merck and Roche, respectively. Other large companies are collaborating with or licensing products from companies developing therapeutics.

The Market, Pipelines, Licensing Opportunities

This report focuses on RNAi and antisense drugs being developed for therapeutics. The report covers the markets for RNAi and antisense drugs based on active pipeline products, size of the markets for different indications, and licensing and business development opportunities. There are more than thirty companies with RNAi and antisense technologies described in detail in this report that are actively out-licensing molecules and platforms in early and late stage development.

Key Information Presented in Figures:

1. RNAi Products in Development by Technology Type
2. RNAi pipelines by Development Stage
3. RNAi/Antisense Products in Development for Cancer Indications
4. RNAi/Antisense Products in Development for Non-cancer Indications
5. Stages of Development for Selected Indications
6. Major RNAi/Antisense Related Activities of Large Pharmaceutical Companies
7. RNAi/Antisense Collaborations with Large Pharmaceutical Companies 2004-2008
8. Number of RNAi and antisense pipelines by target organ

Key Information Presented in Tables:

1. Number of siRNA Pipeline Products
2. Number of Antisense Pipeline Products
3. "Other" RNA technology Pipelines
4. RNAi and Antisense Products in Development by Indications
5. Top Ten Global Therapeutic Classes by 2007 Sales
6. Pipeline Collaborations for Isis Pharmaceutical
7. Collaborations Between Alnylam and Other Companies
8. The Interferx™ program and other IP partners
9. Additional Collaborations Between 2006 – 2008
10. Activities of Large Pharmaceutical Companies in the RNAi and Antisense Space
11. Ligands and their targets
12. Delivery Technologies for RNAi and Antisense
13. Liposomal Technologies for Nucleic Acid Delivery
14. Liposomes Formulated by Ethanol dilution-SNALP Technology

RNAi and Antisense Therapeutics

ORDER FORM

Per Copy Paper copy PDF copy \$4,950

Extra paper copies x _____ \$500 ea.

Note: All prices are U.S. dollars

Total Amount Due: _____

Shipping/Purchase Information

Name _____

Title _____

Company _____

Address _____

Telephone _____

E-mail _____

Facsimile _____

Signature _____

Date _____

Credit card MC Visa Amex

Card number _____

Exp. date _____ Security code (3 or 4 digits) _____

Check enclosed, made payable to Technology Catalysts International

Send invoice to the address above

Wire transfer: please contact TCI directly

Mail, fax or phone orders to:

Ajay Rastogi

Vice President

Technology Catalysts International

605 Park Avenue, Falls Church, VA 22046, USA

Telephone: (703) 531-0257

Facsimile: (703) 237-0042

E-mail: arastogi@technology-catalysts.com